Annotation Detail

Information
Associated Genes
BRAF
Associated Variants
BRAF NRF1-BRAF
Associated Disease
transitional cell carcinoma
Source Database
CIViC Evidence
Description
In a case report, a patient with urothelial carcinoma harboring with NRF1-BRAF fusion was treated with trametinib. After two and a half months of treatment, MRI revealed 48.4% decrease in size of liver metastasis.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/7763
Gene URL
https://civic.genome.wustl.edu/links/genes/5
Variant URL
https://civic.genome.wustl.edu/links/variants/2883
Rating
3
Evidence Type
Predictive
Disease
Urothelial Carcinoma
Evidence Direction
Supports
Drug
Trametinib
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
31010895
Drugs
Drug NameSensitivitySupported
TrametinibSensitivitytrue